A quantitative framework for modeling COVID-19 risk during adjuvant therapy using published randomized trials of glioblastoma in the elderly. Issue 7 (27th April 2020)

• Record Type: Journal Article
• Authors: Tabrizi, Shervin; Trippa, Lorenzo; Cagney, Daniel; Tanguturi, Shyam; Ventz, Steffen; Fell, Geoffrey; Wen, Patrick Y; Alexander, Brian M; Rahman, Rifaquat
• Is Part Of: Neuro-oncology. Volume 22:Issue 7(2020)
• Page Start: 918
• Page End: 927
• Publication Date: 2020-04-27
• Subjects: COVID-19 -- elderly -- glioblastoma -- randomized controlled trials; Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noaa111
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Background: During the ongoing COVID-19 pandemic, contact with the health care system for cancer treatment can increase risk of infection and associated mortality. Treatment recommendations must consider this risk for elderly and vulnerable cancer patients. We reanalyzed trials in elderly glioblastoma (GBM) patients, incorporating COVID-19 risk, in order to provide a quantitative framework for comparing different radiation (RT) fractionation schedules on patient outcomes. Methods: We extracted individual patient-level data for 1321 patients from Kaplan–Meier curves from 5 randomized trials on treatment of elderly GBM patients including available subanalyses based on O 6 -methylguanine-DNA methyltransferase (MGMT) methylation status. We simulated trial data with incorporation of COVID-19–associated mortality risk in several scenarios (low, medium, and high infection and mortality risks). Median overall survival and hazard ratios were calculated for each simulation replicate. Results: Our simulations reveal how COVID-19–associated risks affect survival under different treatment regimens. Hypofractionated RT with concurrent and adjuvant temozolomide (TMZ) demonstrated the best outcomes in low and medium risk scenarios. In frail elderly patients, shorter courses of RT are preferable. In patients with methylated MGMT receiving single modality treatment, TMZ-alone treatment approaches may be an option in settings with high COVID-19–associated risk. Conclusions: Incorporation of COVID-19–associated risk models into analysis of randomized trials can help guide clinical decisions during this pandemic. In elderly GBM patients, our results support prioritization of hypofractionated RT and highlight the utility of MGMT methylation status in decision making in pandemic scenarios. Our quantitative framework can serve as a model for assessing COVID-19 risk associated with treatment across neuro-oncology. Key Points: Re-analysis of randomized controlled trials in COVID-19 era gives insight on optimal treatment of GBM. Hypofractionated RT or temozolomide alone may be reasonable options in high risk pandemic settings. A quantitative framework incorporating COVID-19 risks can be applied across neuro-oncology.